SATIVEX

This brand name is authorized in Estonia, Finland, Ireland, Israel, New Zealand, Poland, Spain, UK.

Active ingredients

The drug SATIVEX contains a combination of these active pharmaceutical ingredients (APIs):

1	Dronabinol UNII 7J8897W37S - DRONABINOL
	Dronabinol is an active ingredient of cannabis, which has complex effects on the CNS, including central sympathomimetic activity. Dronabinol exerts its action by activating CB1 and CB2 recepors which makes it a CNS active medicine.
	Read more about Dronabinol
2	Cannabidiol UNII 19GBJ60SN5 - CANNABIDIOL
	Cannabidiol is indicated for the treatment of seizures associated with Lennox‑Gastaut syndrome (LGS), Dravet syndrome (DS), or tuberous sclerosis complex (TSC) in patients 1 year of age and older.
	Read more about Cannabidiol

Medicine classification

This drug has been classified in the anatomical therapeutic chemical (ATC) classification system as follows:

ATC Group		Classification
N02BG10		N Nervous system → N02 Analgesics → N02B Other analgesics and antipyretics → N02BG Other analgesics and antipyretics
Discover more medicines within N02BG10

Authorization and marketing

This drug has been assigned below unique identifiers within the countries it is being marketed:

Country	Identification scheme	Identifier(s)
EE	Ravimiamet	1645275
ES	Centro de información online de medicamentos de la AEMPS	72544
FI	Lääkealan turvallisuus- ja kehittämiskeskus	173653
GB	Medicines & Healthcare Products Regulatory Agency	174194
IL	מִשְׂרַד הַבְּרִיאוּת	7230
NZ	Medicines and Medical Devices Safety Authority	13391
PL	Rejestru Produktów Leczniczych	100290348